Regulatory
Are Times A-Changing for Drug Marketing?
Less restrictive rules on drug advertising and promotion may be emerging from FDA, as the agency responds to high court decisions questioning government actions that curb communications. Moreover, radical shifts are directing industry promotional efforts away from prescribers and toward informed payers that decide coverage based on broader outcomes data, as opposed to company advertising. Jill Wechsler reports ...Read more
Embedding patient centricity
Understanding the role of real-world evidence in global market access strategies
Live webinar: Tuesday, April 28, 2015 - 11.00 EDT, 17.00 CEST
Join Dr Louise Parmenter, and Dr Stella Blackburn from Qunitiles and Dr Seleen Ong from Pfizer as they discuss the importance of embedding patient centricity into the development of real-world evidence in global market access strategies.  Register for free
Events
The Value of Failure: 5 Indispensible Lessons from SXSW
Janelle Starr rolled into Austin, TX, for the South By Southwest (SXSW) event expecting to hear stories of grand achievements and inspirational actions, but instead found a theme of failure. But some of those failures were enlightening, with speakers sharing what they learned — that the humbling experience of failure was essential to their ultimate success ...Read more
Rare Disease Week: Progress, But Still Very Few Treatments
Steve Smith provides an advocates account of last month's Rare Disease Week, where patient advocates asked legislators to support the new 21st Century Cures draft legislation, a bi-partisan initiative of the U.S. House of Representatives' Energy and Commerce Committee proposing laws that put patients at the center of drug development ...Read more
Special Feature
Pharm Exec’s 11th Annual Press Audit
The Annual Press Audit of issues in the pharmaceutical industry audit tracks and analyzes the industry issues covered by the media. The results of this year’s survey indicate that the media’s scrutiny of pharma increased in 2014, continuing a three-year trend and establishing a five-year high. Drug safety again sits atop of the list of hot button issues, with R&D and healthcare reform next on the list ...Read more
Leadership
Deadline for Nomination: Pharm Exec’s 2015 Emerging Pharma Leaders
Pharm Exec is looking for the fresh faces of pharma leadership, and we’d like your input! Tell us who you think should be included as one of Pharmaceutical Executive’s 2015 Emerging Pharma Leaders. Read more for details of how to nominate a colleague — or yourself. The deadline for this year’s entries is April 15 ...Read more
Regulatory
End of an Era: Hamburg Exits FDA
FDA commissioner Margaret Hamburg has received praise and plaudits as she exits the Food and Drug Administration this week after six years on the job. This past month, she made her final case for boosting FDA’s budget in appearances before House and Senate appropriations committees ...Read more |
|
|
 //REVA Medical (San Diego, CA) appointed Scott Huennekens to its Board of Directors.//Tom Cannellhas joined Orexigen Therapeutics (San Diego, CA) as Chief Commercial Officer.//Pfizer announced that Charles Reay Mackay, Ph.D., will join the company as Chief Scientific Officer for Pfizer's Inflammation and Immunology Research Unit.//Michael D. Webb was appointed President and CEO of both Tyrogenex and Xcovery (Palm Beach Gardens, FL).//StemCells (Newark, CA) announced that Ian Massey, D. Phil., has joined its executive team as President and Chief Operating Officer.// |
|
